Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, Dimitrios Zardavas, Anita Jallitsch-Halper, Lorena de la Peña, Paolo Nuciforo, Alberto Ballestrero, Peter Dubsky, Janine M. Lombard, Peter Vuylsteke, Carlos A. Castaneda, Marco Colleoni, Giuliano Santos Borges, Eva Ciruelos, Monica Fornier, Katalin Boer, Aditya Bardia, Timothy R. Wilson, Thomas J. StoutJerry Y. Hsu, Yi Shi, Martine Piccart, Michael Gnant, José Baselga, Evandro de Azambuja

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences